NASDAQ : ENSC
Ensysce Biosciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.421 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 8.19M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 8.19M |
| Enterprise Value | 7.71M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 19.46M |
| Shares Outstanding | 19.46M |
| Shares Change (YoY) | +393.27% |
| Shares Change (QoQ) | +90.60% |
| Owned by Insiders (%) | 4.72% |
| Owned by Institutions (%) | 4.65% |
| Float | 18.54M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.82 |
| Forward PS | 1.52 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.70 |
| Quick Ratio | 0.27 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -791.69 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -1,295.09% |
| Return on Assets (ROA) | -185.51% |
| Return on Invested Capital (ROIC) | -615.61% |
| Return on Capital Employed (ROCE) | 1,139.82% |
| Weighted Average Cost of Capital (WACC) | 9.76% |
| Revenue Per Employee | $450,075 |
| Profits Per Employee | -$1.26M |
| Employee Count | 10 |
| Asset Turnover | 1.06 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.02 |
| 52-Week Price Change | -79.86% |
| 50-Day Moving Average | 0.45 |
| 200-Day Moving Average | 0.43 |
| Relative Strength Index (RSI) | 40.65 |
| Average Volume (20 Days) | 570,754 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 303,956 |
| Short Previous Month | 1.08M |
| Short % of Shares Out | 1.56% |
| Short % of Float | 1.64% |
| Short Ratio (days to cover) | 0.54 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 4.50M |
| Gross Profit | -7.89M |
| Operating Income | -12.66M |
| Pretax Income | -12.62M |
| Net Income | -12.62M |
| EBITDA | n/a |
| EBIT | -12.66M |
| Loss Per Share | -$1.90 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 676,704 |
| Total Debt | 196,842 |
| Net Cash | 479,862 |
| Net Cash Per Share | $0.02 |
| Equity (Book Value) | -1.11M |
| Book Value Per Share | -0.05 |
| Working Capital | -1.22M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -8.86M |
| Capital Expenditures | -123,643 |
| Depreciation & Amortization | 19,599 |
| Net Borrowing | -208,939 |
| Free Cash Flow | -8.98M |
| FCF Per Share | -$0.46 |
Margins
| Measure | Value |
|---|
| Gross Margin | -175.21% |
| Operating Margin | -281.32% |
| Pretax Margin | -280.50% |
| Profit Margin | -280.48% |
| EBITDA Margin | n/a |
| EBIT Margin | -281.32% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -393.27% |
| Shareholder Yield | n/a |
| Earnings Yield | -452.07% |
| FCF Yield | -109.62% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $5.13 |
| Price Target Difference | 1,117.34% |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Dec 6, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -81.47 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |